HIGHLIGHTS
- who: Saturday and collaborators from the Abstract citation ID: ofac, . SARS-Co, cell specific responses in allogeneic hematopoietic stem cell transplant recipients after second and third dose of BNT162b, mRNA vaccine Iannetta Marco, MD, Ph, have published the Article: Session:, in the Journal: (JOURNAL)
- future: Studies are needed to evaluate the duration of SARS-CoV-2 CMI in HSCT recipients compared to HD.
SUMMARY
Table 1: Clinical characteristics of allo-HSCT recipients and HD Conclusions. An additional 3rd BNT162b2 mRNA_vaccine booster dose seems to enhance CMI in allogenic HSCT recipients. Studies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.